Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic caffeine citrate for apnea prevention in preterm neonates
ACTRN12621001000897Phase 4Not yet recruiting
- Sponsor
- Mansoor Aslamzai
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in apnea of prematurity (AOP) comparing Caffeine citrate with Placebo (2 arms). Primary endpoints: Risk of apnea, Total duration of apnea attacks and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
caffeine
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on ACTRN12621001000897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001000897.